MODERNA COVID-19 VACCINE RNA
Rheumatoid Arthritis (RA)
National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Rheumatoid Arthritis (RA) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naltrexone Truway Health, Inc. | Phase 4 | BBB |
METHOTREXATE National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | BB |
IBUPROFEN Amgen | Phase 3 | BB |
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BB |
Tocilizumab Hoffmann-La Roche | Phase 3 | BB |
View all 38 →
Same molecule, other indications
MODERNA COVID-19 VACCINE RNA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →